WO2008121563A3 - Modified fgf-21 polypeptides and their uses - Google Patents

Modified fgf-21 polypeptides and their uses Download PDF

Info

Publication number
WO2008121563A3
WO2008121563A3 PCT/US2008/057563 US2008057563W WO2008121563A3 WO 2008121563 A3 WO2008121563 A3 WO 2008121563A3 US 2008057563 W US2008057563 W US 2008057563W WO 2008121563 A3 WO2008121563 A3 WO 2008121563A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
modified fgf
fgf
modified
Prior art date
Application number
PCT/US2008/057563
Other languages
French (fr)
Other versions
WO2008121563A2 (en
Inventor
Thomas P Cujec
Roberto Mariani
Putnam Anna-Maria A Hays
William M Keefe
Nick Knudsen
Lillian Ho
Jason Pinkstaff
Vadim Kraynov
Original Assignee
Ambrx Inc
Thomas P Cujec
Roberto Mariani
Putnam Anna-Maria A Hays
William M Keefe
Nick Knudsen
Lillian Ho
Jason Pinkstaff
Vadim Kraynov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL08732507T priority Critical patent/PL2068909T3/en
Priority to AU2008232937A priority patent/AU2008232937B2/en
Application filed by Ambrx Inc, Thomas P Cujec, Roberto Mariani, Putnam Anna-Maria A Hays, William M Keefe, Nick Knudsen, Lillian Ho, Jason Pinkstaff, Vadim Kraynov filed Critical Ambrx Inc
Priority to SI200830701T priority patent/SI2068909T1/en
Priority to MX2009010531A priority patent/MX2009010531A/en
Priority to AT08732507T priority patent/ATE554785T1/en
Priority to KR1020097022588A priority patent/KR101476472B1/en
Priority to KR1020137034998A priority patent/KR20140012199A/en
Priority to CN201710585053.8A priority patent/CN107501407B/en
Priority to CN200880009653.9A priority patent/CN101663046B/en
Priority to CA2682147A priority patent/CA2682147C/en
Priority to JP2010501093A priority patent/JP2010523084A/en
Priority to KR1020167027888A priority patent/KR20160121601A/en
Priority to ES08732507T priority patent/ES2385114T3/en
Priority to EP08732507A priority patent/EP2068909B1/en
Priority to KR1020157014075A priority patent/KR101808787B1/en
Priority to NZ579566A priority patent/NZ579566A/en
Priority to BRPI0809583-3A priority patent/BRPI0809583B1/en
Priority to DK08732507.2T priority patent/DK2068909T3/en
Publication of WO2008121563A2 publication Critical patent/WO2008121563A2/en
Publication of WO2008121563A3 publication Critical patent/WO2008121563A3/en
Priority to IL200749A priority patent/IL200749B/en
Priority to HK09111624.2A priority patent/HK1134239A1/en
Priority to HRP20120522AT priority patent/HRP20120522T1/en
Priority to IL258724A priority patent/IL258724B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Modified FGF-21 polypeptides and uses thereof are provided.
PCT/US2008/057563 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses WO2008121563A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
ES08732507T ES2385114T3 (en) 2007-03-30 2008-03-19 Modified FGF-21 polypeptides and their uses
KR1020167027888A KR20160121601A (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
SI200830701T SI2068909T1 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
AU2008232937A AU2008232937B2 (en) 2007-03-30 2008-03-19 Modified FGF-21 polypeptides and their uses
AT08732507T ATE554785T1 (en) 2007-03-30 2008-03-19 MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
KR1020097022588A KR101476472B1 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
EP08732507A EP2068909B1 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
CN201710585053.8A CN107501407B (en) 2007-03-30 2008-03-19 Modified FGF-21 polypeptides and uses thereof
CN200880009653.9A CN101663046B (en) 2007-03-30 2008-03-19 Through modifying the polypeptides of FGF 21 and its purposes
CA2682147A CA2682147C (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
JP2010501093A JP2010523084A (en) 2007-03-30 2008-03-19 Modified FGF-21 polypeptide
PL08732507T PL2068909T3 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
MX2009010531A MX2009010531A (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses.
KR1020137034998A KR20140012199A (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
KR1020157014075A KR101808787B1 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
NZ579566A NZ579566A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses
BRPI0809583-3A BRPI0809583B1 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptide, composition comprising the same, method for producing said fgf-21 polypeptide, and cell comprising a polynucleotide
DK08732507.2T DK2068909T3 (en) 2007-03-30 2008-03-19 Modified FGF-21 polypeptides and their use
IL200749A IL200749B (en) 2007-03-30 2009-09-06 Modified fgf-21 polypeptides and their uses
HK09111624.2A HK1134239A1 (en) 2007-03-30 2009-12-10 Modified fgf-21 polypeptides and their uses
HRP20120522AT HRP20120522T1 (en) 2007-03-30 2012-06-21 Modified fgf-21 polypeptides and their uses
IL258724A IL258724B (en) 2007-03-30 2018-04-16 Modified fgf-21 polypeptides and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92129707P 2007-03-30 2007-03-30
US60/921,297 2007-03-30
US98806007P 2007-11-14 2007-11-14
US60/988,060 2007-11-14

Publications (2)

Publication Number Publication Date
WO2008121563A2 WO2008121563A2 (en) 2008-10-09
WO2008121563A3 true WO2008121563A3 (en) 2008-11-20

Family

ID=39808850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/057563 WO2008121563A2 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses

Country Status (19)

Country Link
US (8) US8012931B2 (en)
EP (1) EP2068909B1 (en)
JP (4) JP2010523084A (en)
KR (4) KR20160121601A (en)
CN (2) CN107501407B (en)
AT (1) ATE554785T1 (en)
AU (1) AU2008232937B2 (en)
BR (1) BRPI0809583B1 (en)
CA (1) CA2682147C (en)
CY (1) CY1113188T1 (en)
DK (1) DK2068909T3 (en)
ES (1) ES2385114T3 (en)
HK (3) HK1134239A1 (en)
HR (1) HRP20120522T1 (en)
IL (2) IL200749B (en)
MX (1) MX2009010531A (en)
PL (1) PL2068909T3 (en)
PT (1) PT2068909E (en)
WO (1) WO2008121563A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE10163106A1 (en) * 2001-12-24 2003-07-10 Univ Hannover Medical implants, prostheses, prosthesis parts, medical instruments, devices and aids made of a halide-modified magnesium material
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CN107501407B (en) * 2007-03-30 2022-03-18 Ambrx公司 Modified FGF-21 polypeptides and uses thereof
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
AU2013211503C1 (en) * 2008-10-10 2016-09-29 Amgen Inc. FGF21 mutants and uses thereof
CN102625811B (en) * 2008-10-10 2016-09-21 安姆根有限公司 FGF21 mutant and application thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
EP2389190B1 (en) 2009-01-23 2018-09-19 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
EA021425B1 (en) 2009-05-05 2015-06-30 Амген Инк. Fgf21 mutants and uses thereof
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
MX2011013903A (en) 2009-06-17 2012-05-08 Amgen Inc Chimeric fgf19 polypeptides and uses thereof.
CN101993485B (en) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
AU2010317842A1 (en) 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
MX2012006397A (en) * 2009-12-02 2012-11-30 Amgen Inc Binding proteins that bind to human fgfr1c, human î²-klotho and both human fgfr1c and humanî²-klotho.
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
US20130116171A1 (en) 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
JP2013533227A (en) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス FGF21 analogs and derivatives
CN103415300B (en) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 FGF21 compounds end modified N
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN101935346B (en) * 2010-08-24 2012-08-08 哈尔滨博翱生物医药技术开发有限公司 Mutated human-source fibroblast growth factor and application in treating endocrine diseases
SG190082A1 (en) * 2010-11-05 2013-06-28 Covx Technologies Ireland Ltd Anti-diabetic compounds
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CN103797122A (en) * 2011-04-08 2014-05-14 安瑟生物科技私人有限公司 Novel expression and secretion vector systems for heterologous protein production in escherichia coli
WO2012140650A2 (en) * 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
US8754044B2 (en) * 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
TWI527590B (en) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Freeze-dried formulations of fgf-18
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
AR087973A1 (en) 2011-10-04 2014-04-30 Lilly Co Eli VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
EA025662B1 (en) 2011-10-07 2017-01-30 Такеда Фармасьютикал Компани Лимитед 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
WO2013093720A2 (en) * 2011-12-22 2013-06-27 Pfizer Inc. Anti-diabetic compounds
CN108103069B (en) 2012-02-15 2021-08-10 诺和诺德股份有限公司 Antibodies that bind to and block trigger receptor-1 (TREM-1) expressed by myeloid cells
PL2814842T3 (en) 2012-02-15 2018-12-31 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
PE20142432A1 (en) * 2012-05-15 2015-01-22 Lilly Co Eli THERAPEUTIC USES OF PROTEINS FROM THE FIBROBLAST GROWTH FACTOR 21
US9464126B2 (en) * 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
TWI513705B (en) * 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
US8955588B2 (en) * 2012-09-10 2015-02-17 Halliburton Energy Services, Inc. Electron-poor orthoester for generating acid in a well fluid
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2915851T3 (en) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc FGF19 chimeric peptides for use in the treatment of bile acid disorders
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
MX2016005101A (en) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Mutated fibroblast growth factor (fgf) 1 and methods of use.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (en) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antibodies binding beta klotho domain 2 and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TN2017000008A1 (en) 2014-07-17 2018-07-04 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
CN107108711B (en) 2014-10-23 2021-11-23 恩格姆生物制药公司 Pharmaceutical compositions comprising peptide variants and methods of use thereof
PT3412302T (en) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
PT3236991T (en) 2014-12-23 2019-09-06 Novo Nordisk As Fgf21 derivatives and uses thereof
KR20160088656A (en) 2015-01-16 2016-07-26 주식회사유한양행 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
CN105018482B (en) * 2015-07-21 2017-10-24 吉林大学 A kind of heterozygosis tRNA and its application in glutathione peroxidase is prepared
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2018535964A (en) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analog
ES2871036T3 (en) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Method for treating bile acid-related disorders
US10617765B2 (en) * 2015-11-23 2020-04-14 Bristol-Myers Squibb Company Additive systems for use in protein PEGylation
TW201731867A (en) 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variants
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
CN107759694B (en) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (en) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
US20190201491A1 (en) * 2016-08-22 2019-07-04 Elanco Us Inc. Bovine fibroblast growth factor 21 and ketosis in dairy cattle
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110637027A (en) 2017-02-08 2019-12-31 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
ES2930534T3 (en) * 2017-09-04 2022-12-16 89Bio Ltd Mutant FGF-21 Peptide Conjugates and Uses Thereof
BR112020004136A2 (en) 2017-09-08 2020-09-08 Bristol-Myers Squibb Company modified fibroblast growth factor 21 (fgf-21) for use in non-alcoholic steatohepatitis (nash) treatment methods
CN109929806B (en) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 Stem cell expressing GLP1 and FGF21 and application thereof
JOP20200240A1 (en) 2018-04-02 2020-09-27 Bristol Myers Squibb Co Anti-trem-1 antibodies and uses thereof reference to sequence listing submitted electronically via efs-web
BR112020026512A2 (en) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company FGF-21 FORMULATIONS
KR20210090649A (en) 2018-11-05 2021-07-20 브리스톨-마이어스 스큅 컴퍼니 Methods for Purification of PEGylated Proteins
CN111195234B (en) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 Recombinant FGF21-Fc fusion protein freeze-dried powder preparation
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
TW202140074A (en) 2020-01-08 2021-11-01 美商必治妥美雅史谷比公司 Fgf-21 conjugate formulations
CN113728013B (en) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Conjugates of fusion proteins of GLP-1 and FGF21
US20230090114A1 (en) * 2020-01-31 2023-03-23 89Bio Ltd. Methods for promoting weight loss
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194256A1 (en) * 2004-12-22 2006-08-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7259248B2 (en) * 1999-11-18 2007-08-21 Chiron Corporation Human FGF-21 polypeptides

Family Cites Families (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2968158A (en) * 1955-08-08 1961-01-17 Upjohn Co New benzene sulfonyl ureas; composition and process for lowering blood sugar therewith
US3097242A (en) * 1960-06-29 1963-07-09 Olin Mathieson Hydrindene sulfonylureas
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
NL132376C (en) * 1966-02-10
US3668215A (en) * 1967-11-25 1972-06-06 Bayer Ag Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
CH505073A (en) * 1968-04-26 1971-03-31 Hoffmann La Roche Sulphonylurea derivs hypoglycaemic
NL138933B (en) * 1969-03-26 1973-05-15 Erba Carlo Spa PROCEDURE FOR PREPARING BENZENE SULPHONYLUREA DERIVATIVES WITH BLOOD SUGAR-MIRROR-LOWERING ACTION.
US3708486A (en) * 1969-04-17 1973-01-02 Boehringer Sohn Ingelheim 2-(p-(n'-cycloalkyl-carbamido-n-sulfonyl)-phenethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4,4-dimethyl-isoquinolines and alkali metal salts thereof
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (en) * 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4820352A (en) 1983-01-10 1989-04-11 Bausch & Lomb Incorporated Cleaning and conditioning solutions for contact lenses and methods of use
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US5089398A (en) * 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
JPS59166086A (en) 1983-03-09 1984-09-19 Teruhiko Beppu Novel development type plasmid and development of vitular prochymosin gene in escherichia coli using it
US4859600A (en) * 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
DE3320583A1 (en) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (en) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd Preparation of liposome
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4689406A (en) * 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
ATE159858T1 (en) * 1983-09-26 1997-11-15 Ehrenfeld Udo AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLULAR AND HUMORAL IMMUNE DEFENSE
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DK518384A (en) 1984-01-31 1985-07-01 Idaho Res Found VECTOR FOR THE MANUFACTURE OF A GENE PRODUCT IN INSECT CELLS, PROCEDURE FOR ITS MANUFACTURING AND ITS USE
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4880734A (en) * 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
CA1336076C (en) 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
JPS63123383A (en) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp Hybrid promoter, manifestation regulating dna sequence and manifestation vector
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
EP0349594A4 (en) 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
JP2795850B2 (en) 1987-03-23 1998-09-10 ザイモジェネティクス，インコーポレイティド Yeast expression vector
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1989001037A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
WO1989001038A1 (en) 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
US5674706A (en) * 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
FR2631974B1 (en) * 1988-05-31 1992-12-11 Agronomique Inst Nat Rech MODIFIED BACULOVIRUS, ITS PREPARATION METHOD AND ITS APPLICATION AS A GENE EXPRESSION VECTOR
WO1990001556A1 (en) 1988-08-05 1990-02-22 Mount Sinai School Of Medicine Of The City University Of New York In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
EP0446299A4 (en) 1988-11-18 1992-05-13 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
DE68925966T2 (en) 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
WO1990010078A1 (en) 1989-02-23 1990-09-07 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
EP0460071A4 (en) 1989-02-24 1993-02-03 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JP2875884B2 (en) 1989-04-19 1999-03-31 ノボ ノルディスク アクティーゼルスカブ Active polyalkylene oxide carbonates for use in modifying polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
WO1990014428A1 (en) 1989-05-17 1990-11-29 University Of Georgia Research Foundation, Inc. Improved baculovirus expression vectors
ATE136315T1 (en) 1989-05-27 1996-04-15 Sumitomo Pharma METHOD FOR THE PRODUCTION OF POLYETHYLENE GLYCOL DERIVATIVES AND MODIFIED PROTEINS.
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5162601A (en) * 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
FR2664905B1 (en) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech MODIFIED BACULOVIRUS, PROCESS FOR OBTAINING SAME, AND EXPRESSION VECTORS OBTAINED FROM SAID BACULOVIRUS.
WO1992001800A1 (en) * 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
JPH06501845A (en) 1990-08-02 1994-03-03 カイロン　コーポレイション Expression of human CMV glycoprotein-H using a baculovirus-insect cell expression system
CA2090969C (en) * 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
EP0513332A4 (en) * 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JPH06506217A (en) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
WO1992016619A1 (en) 1991-03-19 1992-10-01 Us Army Expression of influenza nucleoprotein antigens in baculovirus
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6013433A (en) 1991-04-26 2000-01-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
IT1260468B (en) 1992-01-29 1996-04-09 METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
IL104734A0 (en) * 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5874454A (en) 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5491076A (en) * 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
US5605792A (en) * 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
FR2715664B1 (en) 1994-01-31 1996-04-12 Proteine Performance Sa Recombinant baculovirus and its use for the production of monoclonal antibodies.
JP3090586B2 (en) * 1994-03-15 2000-09-25 片倉工業株式会社 Baculovirus deficient in cysteine protease gene, method for producing the same, and method for producing useful protein using the same
US5473034A (en) * 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
WO1995033490A1 (en) 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US6852502B1 (en) 1995-06-06 2005-02-08 Bioveris Corporation Electrochemiluminescent enzyme biosensors
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2223125A1 (en) 1995-02-17 1996-08-22 Stichting Instituut Voor Dierhouderij En Diergezondheid Production of biologically active recombinant bovine follicle stimulating hormone (recbfsh) in the baculovirus expression system
FR2732035B1 (en) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech METHOD FOR REGULATING THE EXPRESSION OF A GENE IN A BACULOVIRUS, BY A FIXATION SITE OF A RETINOIC ACID RECEPTOR, AND VECTOR FOR CARRYING OUT SAID METHOD
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
AU1690697A (en) 1996-01-17 1997-08-11 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2262994A1 (en) 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
ATE398139T1 (en) 1996-12-13 2008-07-15 Novartis Vaccines & Diagnostic ANALYSIS AND SEPARATION OF PDGF PROTEINS
JP2001508783A (en) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー PEGylation method
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
JP2002505574A (en) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド Polyalkylene oxide-modified single-chain polypeptides
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU744085B2 (en) 1997-06-06 2002-02-14 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
WO1999007862A1 (en) 1997-08-05 1999-02-18 Chiron Corporation Novel pichia pastoris gene sequences and methods for their use
DE19735593C2 (en) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
AU9393398A (en) 1997-09-16 1999-04-05 Egea Biosciences, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
JP2001517686A (en) 1997-09-26 2001-10-09 ユーエイビー リサーチ ファンデーション Blood cells with reduced antigenicity and uses thereof
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
DE19748489A1 (en) 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylene glycol-derivatized biomolecules and their use in heterogeneous detection methods
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6225060B1 (en) 1998-03-04 2001-05-01 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
JP4078032B2 (en) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション Poly (ethylene glycol) derivatives with proximal reactive groups
KR100264953B1 (en) 1998-04-03 2001-03-02 박현우 Recombinant baculovirus, process for preparing thereof and microbial insecticides containing same
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
AU764144B2 (en) 1998-08-28 2003-08-14 Gryphon Therapeutics, Inc. Polyamide chains of precise length, methods to manufacture them and their conjugates
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000026354A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
EP1177311B1 (en) 1999-03-17 2014-11-12 The Board Of Trustees Of The Leland Stanford Junior University In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
DE60026983T2 (en) 1999-04-16 2007-01-25 William Marsh Rice University, Houston FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE COETHYLENE GLYCOL
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
ATE271049T1 (en) 1999-11-10 2004-07-15 Takeda Chemical Industries Ltd FIVE-MEMBED N-HETEROCYCLES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC EFFECTS
EP1232264B1 (en) * 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Human fgf-21 gene and gene expression products
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
PT1259563E (en) 1999-12-22 2009-04-14 Nektar Therapeutics Al Corp Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
WO2001068854A2 (en) * 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
JP2002030098A (en) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd Method for recovering virion envelope from budded virus of baculovirus
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1318827A4 (en) 2000-09-08 2005-09-14 Gryphon Therapeutics Inc Polymer-modified synthetic proteins
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7045337B2 (en) 2001-04-19 2006-05-16 The Scripps Research Institute In vivo incorporation of unnatural amino acids
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2556338T3 (en) * 2001-10-10 2016-01-15 Novo Nordisk A/S Remodeling and glycoconjugation of peptides
EP1437351A4 (en) 2001-10-19 2005-06-01 Takeda Pharmaceutical Amine derivative
MXPA04004336A (en) 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Branched polymers and their conjugates.
US7884182B2 (en) 2001-11-14 2011-02-08 Amylin Pharmaceuticals, Inc. Chemical peptide ligation with three or more components
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
WO2003059270A2 (en) 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
JP4464684B2 (en) 2002-02-15 2010-05-19 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク アト バッファロー Ribozymes with broad tRNA aminoacylation activity
DE60332725D1 (en) 2002-05-30 2010-07-08 Scripps Research Inst COPPER-CATALYZED LEADING OF AZIDES AND ACETYLENES
KR20050073559A (en) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 Glycoprotein synthesis
KR20050072441A (en) 2002-10-16 2005-07-11 더 스크립스 리서치 인스티튜트 Site specific incorporation of keto amino acids into proteins
EP1583816A4 (en) 2002-12-22 2007-06-13 Scripps Research Inst Protein arrays
CN100522988C (en) * 2003-04-09 2009-08-05 诺和诺德公司 Glycopegylation methods and proteins/peptides produced by the methods
AU2004233083B2 (en) 2003-04-17 2010-09-16 The Scripps Research Institute Expanding the eukaryotic genetic code
BRPI0411112A (en) 2003-06-12 2006-07-18 Lilly Co Eli heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
EP1649004A4 (en) 2003-07-07 2008-04-09 Scripps Research Inst Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
WO2005061712A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20090111742A1 (en) 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
US7896406B2 (en) 2004-01-30 2011-03-01 Certainteed Corporation Hose connector
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
ZA200606216B (en) * 2004-02-02 2007-11-28 Ambrx Inc Modified human interferon polypeptides and their uses
JP2007531715A (en) * 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー Glycol-linked FGF-21 compound
SI1751184T1 (en) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fusion proteins
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1789442B1 (en) 2004-09-02 2009-09-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1814573B1 (en) * 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7655627B2 (en) * 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
MX2007007587A (en) 2004-12-22 2007-12-11 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid.
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
KR20080026120A (en) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 Incorporation of non-naturally encoded amino acids into proteins
MX2008002149A (en) 2005-08-18 2008-04-22 Ambrx Inc COMPOSITIONS OF tRNA AND USES THEREOF.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
SG170116A1 (en) 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2632832A1 (en) 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008083346A1 (en) 2006-12-28 2008-07-10 Ambrx, Inc. Phenazine and quinoxaline substituted amino acids and polypeptides
CN107501407B (en) 2007-03-30 2022-03-18 Ambrx公司 Modified FGF-21 polypeptides and uses thereof
EP2173890B1 (en) 2007-06-21 2011-03-16 Technische Universität München Biological active proteins having increased in vivo and/or vitro stability
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
CN102625811B (en) 2008-10-10 2016-09-21 安姆根有限公司 FGF21 mutant and application thereof
EP2389190B1 (en) 2009-01-23 2018-09-19 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
CN102802657A (en) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 GLP-1 and FGF21 combinations for treatment of diabetes type 2
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP2013533227A (en) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス FGF21 analogs and derivatives
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US20140221287A1 (en) 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Amylin Peptides and Derivatives and Uses Thereof
UY34346A (en) 2011-09-26 2013-04-30 Novartis Ag FUSION PROTEINS TO TREAT METABOLIC DISORDERS
AR087973A1 (en) 2011-10-04 2014-04-30 Lilly Co Eli VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
TWI513705B (en) 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
MA37963A1 (en) 2012-09-07 2018-06-29 Sanofi Sa Fusion Proteins to Treat a Metabolic Syndrome
CN103923207B (en) 2014-04-08 2016-03-09 东北农业大学 A kind of preparation of FGF-21 mutant protein and the application in treatment non-alcoholic fatty liver disease thereof
PT3412302T (en) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259248B2 (en) * 1999-11-18 2007-08-21 Chiron Corporation Human FGF-21 polypeptides
US20060194256A1 (en) * 2004-12-22 2006-08-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof

Also Published As

Publication number Publication date
BRPI0809583B1 (en) 2022-02-22
HK1204331A1 (en) 2015-11-13
US10377805B2 (en) 2019-08-13
CY1113188T1 (en) 2016-04-13
US9517273B2 (en) 2016-12-13
HK1134239A1 (en) 2010-04-23
HRP20120522T1 (en) 2012-08-31
JP2020018314A (en) 2020-02-06
PL2068909T3 (en) 2012-09-28
US8383365B2 (en) 2013-02-26
JP2010523084A (en) 2010-07-15
IL258724A (en) 2018-06-28
US20200031894A1 (en) 2020-01-30
EP2068909A2 (en) 2009-06-17
ES2385114T3 (en) 2012-07-18
US20110172401A1 (en) 2011-07-14
DK2068909T3 (en) 2012-08-06
US20170096463A1 (en) 2017-04-06
KR20160121601A (en) 2016-10-19
US9975936B2 (en) 2018-05-22
AU2008232937B2 (en) 2012-09-27
US9079971B2 (en) 2015-07-14
KR20150064249A (en) 2015-06-10
HK1248715A1 (en) 2018-10-19
JP2017212986A (en) 2017-12-07
IL200749A0 (en) 2010-05-17
US20210261637A1 (en) 2021-08-26
KR20140012199A (en) 2014-01-29
ATE554785T1 (en) 2012-05-15
AU2008232937A1 (en) 2008-10-09
CA2682147C (en) 2017-08-08
PT2068909E (en) 2012-07-04
CN104163864B (en) 2017-08-01
US20130150564A1 (en) 2013-06-13
CN104163864A (en) 2014-11-26
EP2068909B1 (en) 2012-04-25
JP2015057404A (en) 2015-03-26
CA2682147A1 (en) 2008-10-09
US10961291B2 (en) 2021-03-30
US20080255045A1 (en) 2008-10-16
WO2008121563A2 (en) 2008-10-09
KR101808787B1 (en) 2017-12-13
IL258724B (en) 2021-06-30
JP6158158B2 (en) 2017-07-05
BRPI0809583A2 (en) 2019-09-03
CN107501407B (en) 2022-03-18
US20150273075A1 (en) 2015-10-01
IL200749B (en) 2019-06-30
KR20100016014A (en) 2010-02-12
MX2009010531A (en) 2009-11-26
CN107501407A (en) 2017-12-22
KR101476472B1 (en) 2015-01-05
US8012931B2 (en) 2011-09-06
US20180298073A1 (en) 2018-10-18
EP2068909A4 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
WO2008121563A3 (en) Modified fgf-21 polypeptides and their uses
WO2009067636A3 (en) Modified insulin polypeptides and their uses
WO2008137471A3 (en) Modified interferon beta polypeptides and their uses
WO2010011735A3 (en) Modified bovine g-csf polypeptides and their uses
HRP20181353T1 (en) The tuberculosis rv2386c protein, compositions and uses thereof
WO2009100255A3 (en) Modified leptin polypeptides and their uses
WO2009036460A3 (en) Modified human apolipoprotein a-i polypeptides and their uses
WO2006133088A3 (en) Improved human interferon molecules and their uses
EP2076604A4 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
IL188611A0 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
GB0708376D0 (en) Novel polypeptides and uses thereof
IL190781A0 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
SI2068909T1 (en) Modified fgf-21 polypeptides and their uses
GB0621513D0 (en) Novel polypeptides and uses thereof
ZA200804502B (en) GLP-2 mimetibodies, polypeptides, compositions, methods and uses
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
AU2008902600A0 (en) Polypeptides and uses thereof
IL242077A0 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
AU2005905904A0 (en) Leukocyte-binding polypeptides and uses thereof
AU2007906289A0 (en) Bovine polypeptides and polynucleotides encoding the same
AU2007904259A0 (en) Polypeptides and polynucleotides encoding the same
AU2007900470A0 (en) Protein construct
AU2006904073A0 (en) Biomedicinals and their uses
AU2007903936A0 (en) Viral polypeptides and methods
AU2007903625A0 (en) www.carbonrealestate.com

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009653.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732507

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008732507

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200749

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 579566

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008232937

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2682147

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010501093

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010531

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008232937

Country of ref document: AU

Date of ref document: 20080319

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20097022588

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6386/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0809583

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090929